Trial Profile
The phaseI,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms GAS Study I/II
- 02 Sep 2022 Date analysis concluded 30 Nov 2021, according to UMIN record
- 02 Sep 2022 Status changed from recruiting to completed.
- 12 Nov 2021 Primary endpoint (Phase II: 2-year overall survival (OS) rate and median OS time) has been met, as per results published in the European Journal of Cancer.